Education
About Us
Working with TipRanks
Follow Us
Denali Therapeutics (DNLI)
NASDAQ:DNLI
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 330.53M | $ 108.46M | $ 48.66M | $ 335.66M |
| Gross Profit | $ 0.00 | $ 330.53M | $ 108.46M | $ 48.66M | $ 335.66M |
| Operating Income | $ -487.34M | $ -196.70M | $ -340.74M | $ -295.75M | $ 62.72M |
| EBITDA | $ -492.89M | $ -179.97M | $ -330.36M | $ -287.16M | $ 71.25M |
| Net Income | $ -422.77M | $ -145.22M | $ -325.99M | $ -290.58M | $ 71.14M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 832.33M | $ 1.03B | $ 1.34B | $ 865.41M | $ 1.47B |
| Total Assets | $ 1.37B | $ 1.15B | $ 1.46B | $ 1.40B | $ 1.60B |
| Total Debt | $ 48.71M | $ 52.24M | $ 60.35M | $ 64.01M | $ 68.86M |
| Net Debt | $ -126.25M | $ -74.86M | $ -157.69M | $ -229.47M | $ -438.28M |
| Total Liabilities | $ 144.50M | $ 122.96M | $ 417.81M | $ 441.87M | $ 453.75M |
| Stockholders' Equity | $ 1.23B | $ 1.03B | $ 1.04B | $ 962.29M | $ 1.15B |
| Cash Flow | |||||
| Free Cash Flow | $ -363.61M | $ -370.93M | $ -262.55M | $ -219.89M | $ 413.06M |
| Operating Cash Flow | $ -347.69M | $ -357.99M | $ -244.72M | $ -211.39M | $ 416.15M |
| Investing Cash Flow | $ -88.76M | $ 249.31M | $ -141.39M | $ -21.63M | $ -623.21M |
| Financing Cash Flow | $ 484.30M | $ 17.82M | $ 310.67M | $ 19.35M | $ 634.75M |